Hepatocellular Carcinoma
Conditions
Keywords
HCC, Hepatocellular Carcinoma, MRI, Liver
Brief summary
This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).
Interventions
PROCEDUREMRI Scan of the Liver enhanced with Eovist
10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
Sponsors
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
University of California, San Francisco
San Francisco Veterans Affairs Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Alpha-feto protein \> 400 ng / mL or * prior ultrasound with mass suspicious for hepatic malignancy or. * clinical risk of hepatocellular carcinoma or * prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma
Exclusion criteria
* Glomerulo-filtration rate \< 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study * Previous diagnosis of hepatic malignancy * Any conditions that would discount the ability to have an MRI scan
Countries
United States
Outcome results
None listed